Skip to search formSkip to main contentSkip to account menu

Certican

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
The proliferation signal inhibitor everolimus (Certican), has demonstrated efficacy with full‐dose cyclosporine (CsA) (Neoral… 
Review
2006
Review
2006
Everolimus (Certican) is an orally administered mammalian target of rapamycin inhibitor (proliferation signal inhibitor) derived… 
Review
2005
Review
2005
The calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy in recent years, though their… 
2005
2005
Background. Everolimus (Certican), a novel proliferation signal inhibitor, allows calcineurin inhibitor dose reduction in… 
Review
2005
Review
2005
Everolimus (Certican) is a novel proliferation signal inhibitor with potent immunosuppressant effects that has been shown to… 
Highly Cited
2004
Highly Cited
2004
Background. Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection… 
Review
2002
Review
2002
  • B. Nashan
  • Expert opinion on investigational drugs
  • 2002
  • Corpus ID: 41605993
Everolimus (Certican™) is being developed for prevention of acute and chronic rejection of solid organ transplants. A novel… 
Review
2002
Review
2002
  • B. Nashan
  • Therapeutic drug monitoring
  • 2002
  • Corpus ID: 33394395
SDZ RAD (everolimus, Certican™) is a novel macrolide immunosuppressant that blocks growth factor-driven transduction signals in…